Regulatory News Item

RNS Number : 4445B
Smiths Group PLC
07 June 2019
 

 

News Release

London, 7 June 2019

For immediate release

 

Appointment of Smiths Medical CEO

 

Smiths Group plc is pleased to announce the appointment of JehanZeb Noor as Chief Executive Officer of Smiths Medical. JehanZeb will be part of Smiths Group's Executive Committee and report to Andy Reynolds Smith, CEO of Smiths Group plc.

JehanZeb will take up the role on 1 July 2019 and will oversee the separation of Smiths Medical, which is expected to be completed during the first half of CY2020.

JehanZeb joins from Amcor Flexibles Inc. ('Amcor'), where he led the Healthcare North America business and Global Sales for Medical.  Amcor is a specialist producer of sterile packaging for the global medical device and pharmaceuticals industries.  During his three-year tenure at Amcor he drove a significant improvement in margin and revenue growth and led the integration of a major acquisition.  Prior to joining Amcor, JehanZeb was a Partner at McKinsey & Company where he served for 9 years.  He has a deep understanding of the MedTech supply chain, operations, distribution, product development and regulatory approval processes.  JehanZeb holds a BSc in Finance and a BSc and MSc in Mechanical Engineering from the Massachusetts Institute of Technology.

Andy Reynolds Smith, Chief Executive of Smiths Group, commented:

 "I look forward to working with JehanZeb as we continue building a strong, sustainable future for Smiths Medical and progress the separation of the business from Smiths Group. I am confident that JehanZeb's intimate understanding of the MedTech industry combined with his strong track record of effective leadership, delivering growth and enhanced performance will make him a great success."

JehanZeb Noor, Smiths Medical Chief Executive Officer Designate, commented:

"Smiths Medical is an industry leader, offering high quality specialised medical devices across the globe with significant investment in new products. The company will begin an exciting new chapter when it separates from the wider Group and I'm looking forward to the opportunity to join the team and lead the journey ahead to achieve our full potential, while serving a life saving mission."

END

 

 

Enquiries:

 

Investor enquiries

 

Jemma Spalton, Smiths Group

+44 (0)20 7004 1637

+44 (0)78 6739 0350

jemma.spalton@smiths.com

 

Marion Le Bot, Smiths Group
+44 (0)20 7004 1672
+44 (0)75 8315 4386
marion.lebot@smiths.com

 

Media enquiries

 

Deborah Scott, FTI Consulting
+44 (0)20 3727 1459
+44 (0)797 953 7449
smiths@fticonsulting.com

 

Alex Le May, FTI Consulting
+44 (0)20 3727 1308
+44 (0)7702 443 312
smiths@fticonsulting.com

 

 

 

 

Legal Entity Identifier (LEI): 213800MJL6IPZS3ASA11

 

About Smiths Group

Smiths is a global technology company listed on the London Stock Exchange (SMIN) and operates a sponsored level one ADR programme (SMGZY). Its businesses share common characteristics (well-positioned in growing markets, technology-led, asset-light, digitising, with a high proportion of aftermarket revenues) and a common operating model (The Smiths Excellence System). For more information visit www.smiths.com.

 

About Smiths Medical

Smiths Medical is a leading supplier of specialised medical devices and equipment for global markets, focusing on medication delivery, vital care and safety devices. For more information visit www.smiths-medical.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFMATMBAMBLL